AKERO THERAPEUTICS INC (AKRO)
US00973Y1082 - Common Stock
Taking everything into account, AKRO scores 2 out of 10 in our fundamental rating. AKRO was compared to 564 industry peers in the Biotechnology industry. The financial health of AKRO is average, but there are quite some concerns on its profitability. AKRO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year AKRO has reported negative net income.
In the past year AKRO has reported a negative cash flow from operations.
AKRO had negative earnings in each of the past 5 years.
AKRO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -29.02%, AKRO is doing good in the industry, outperforming 70.02% of the companies in the same industry.
The Return On Equity of AKRO (-32.13%) is better than 77.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.02% | ||
| ROE | -32.13% | ||
| ROIC | N/A |
ROA(3y)-36.37%
ROA(5y)-33.96%
ROE(3y)-40.75%
ROE(5y)-37.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AKRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for AKRO has been increased compared to 1 year ago.
The number of shares outstanding for AKRO has been increased compared to 5 years ago.
The debt/assets ratio for AKRO is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 13.36 indicates that AKRO is not in any danger for bankruptcy at the moment.
AKRO's Altman-Z score of 13.36 is amongst the best of the industry. AKRO outperforms 89.77% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that AKRO is not too dependend on debt financing.
AKRO has a worse Debt to Equity ratio (0.05) than 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
AKRO has a Current Ratio of 17.25. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.
AKRO's Current ratio of 17.25 is amongst the best of the industry. AKRO outperforms 92.28% of its industry peers.
A Quick Ratio of 17.25 indicates that AKRO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 17.25, AKRO belongs to the top of the industry, outperforming 92.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.25 | ||
| Quick Ratio | 17.25 |
3. Growth
3.1 Past
The earnings per share for AKRO have decreased strongly by -59.57% in the last year.
EPS 1Y (TTM)-59.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, AKRO will show a very strong growth in Earnings Per Share. The EPS will grow by 21.00% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.45%
EPS Next 2Y-30.15%
EPS Next 3Y-18.81%
EPS Next 5Y21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AKRO. In the last year negative earnings were reported.
Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AKRO's earnings are expected to decrease with -18.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.15%
EPS Next 3Y-18.81%
5. Dividend
5.1 Amount
AKRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AKERO THERAPEUTICS INC
NASDAQ:AKRO (1/2/2025, 3:11:00 PM)
28.02
+0.2 (+0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.14%
Inst Owner Change0.63%
Ins Owners1.72%
Ins Owner Change3.56%
Market Cap1.96B
Analysts83.33
Price Target49.16 (75.45%)
Short Float %5.58%
Short Ratio5.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.16%
Min EPS beat(2)-13.96%
Max EPS beat(2)11.64%
EPS beat(4)2
Avg EPS beat(4)-1.9%
Min EPS beat(4)-13.96%
Max EPS beat(4)11.64%
EPS beat(8)5
Avg EPS beat(8)7.01%
EPS beat(12)7
Avg EPS beat(12)3.61%
EPS beat(16)9
Avg EPS beat(16)4.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.03%
PT rev (3m)5.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)3.28%
EPS NY rev (3m)-5.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.65 | ||
| P/tB | 2.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.75
EYN/A
EPS(NY)-4.83
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS0
BVpS10.58
TBVpS10.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.02% | ||
| ROE | -32.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.37%
ROA(5y)-33.96%
ROE(3y)-40.75%
ROE(5y)-37.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.25 | ||
| Quick Ratio | 17.25 | ||
| Altman-Z | 13.36 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.89%
EPS Next Y-39.45%
EPS Next 2Y-30.15%
EPS Next 3Y-18.81%
EPS Next 5Y21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-97.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-83.38%
EBIT Next 3Y-26.12%
EBIT Next 5Y22.39%
FCF growth 1Y-126.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-125.87%
OCF growth 3YN/A
OCF growth 5YN/A